Quality standards for managing children and adolescents with bronchiectasis: an international consensus

The global burden of bronchiectasis in children and adolescents is being recognised increasingly. However, marked inequity exists between, and within, settings and countries for resources and standards of care afforded to children and adolescents with bronchiectasis compared with those with other chronic lung diseases. The European Respiratory Society (ERS) clinical practice guideline for the management of bronchiectasis in children and adolescents was published recently. Here we present an international consensus of quality standards of care for children and adolescents with bronchiectasis based upon this guideline. The panel used a standardised approach that included a Delphi process with 201 respondents from the parents and patients’ survey, and 299 physicians (across 54 countries) who care for children and adolescents with bronchiectasis. The seven quality standards of care statements developed by the panel address the current absence of quality standards for clinical care related to paediatric bronchiectasis. These internationally derived, clinician-, parent- and patient-informed, consensus-based quality standards statements can be used by parents and patients to access and advocate for quality care for their children and themselves, respectively. They can also be used by healthcare professionals to advocate for their patients, and by health services as a monitoring tool, to help optimise health outcomes. Child-BEAR-Net has developed internationally derived, clinician-, parent- and patient-informed, consensus-based quality standards of care statements that patients and parents can use to access and advocate for quality care https://bit.ly/3w0tweP

[1]  A. Chang,et al.  European Respiratory Society statement for defining respiratory exacerbations in children and adolescents with bronchiectasis for clinical trials , 2022, European Respiratory Journal.

[2]  A. Chang,et al.  International consensus statement on quality standards for managing children/adolescents with bronchiectasis from the ERS CRC Child-BEAR-Net , 2022, European Respiratory Journal.

[3]  A. Chang,et al.  Children's Bronchiectasis Education Advocacy and Research Network (Child-BEAR-Net): an ERS Clinical Research Collaboration on improving outcomes of children and adolescents with bronchiectasis , 2021, European Respiratory Journal.

[4]  A. Chang,et al.  Management of children and adolescents with bronchiectasis: summary of the ERS clinical practice guideline , 2021, Breathe.

[5]  I. Masters,et al.  Clinical and research priorities for children and young people with bronchiectasis: an international roadmap , 2021, ERJ Open Research.

[6]  A. Chang,et al.  European Respiratory Society guidelines for the management of children and adolescents with bronchiectasis , 2021, European Respiratory Journal.

[7]  C. Byrnes,et al.  Transitioning from paediatric to adult services with cystic fibrosis or bronchiectasis: What is the impact on engagement and health outcomes? , 2020, Journal of paediatrics and child health.

[8]  J. Chalmers,et al.  Counting the cost of bronchiectasis , 2020, Respirology.

[9]  I. Masters,et al.  Cost of hospitalization for bronchiectasis exacerbation in children , 2020, Respirology.

[10]  J. Widger,et al.  Children with bronchiectasis have poorer lung function than those with cystic fibrosis and do not receive the same standard of care , 2019, Pediatric pulmonology.

[11]  R. Ware,et al.  Efficacy of oral amoxicillin–clavulanate or azithromycin for non-severe respiratory exacerbations in children with bronchiectasis (BEST-1): a multicentre, three-arm, double-blind, randomised placebo-controlled trial , 2019, The Lancet Respiratory Medicine.

[12]  Yolanda G. Lovie-Toon,et al.  Health-resource use and quality of life in children with bronchiectasis: a multi-center pilot cohort study , 2019, BMC Health Services Research.

[13]  Cylie M. Williams,et al.  A novel counterbalanced implementation study design: methodological description and application to implementation research , 2019, Implementation Science.

[14]  R. Diel,et al.  Incidence of patients with non-cystic fibrosis bronchiectasis in Germany - A healthcare insurance claims data analysis. , 2019, Respiratory medicine.

[15]  M. Tunney,et al.  British Thoracic Society Guideline for bronchiectasis in adults , 2018, Thorax.

[16]  A. Chang,et al.  Paediatric and adult bronchiectasis: Monitoring, cross‐infection, role of multidisciplinary teams and self‐management plans , 2018, Respirology.

[17]  A. Chang,et al.  Bronchiectasis , 2018, Nature Reviews Disease Primers.

[18]  Tanya Marchant,et al.  High-quality health systems in the Sustainable Development Goals era: time for a revolution , 2018, The Lancet. Global health.

[19]  A. Chang,et al.  Bronchiectasis in children: diagnosis and treatment , 2018, The Lancet.

[20]  M. Martínez-García,et al.  Cost of Hospitalizations due to Exacerbation in Patients with Non-Cystic Fibrosis Bronchiectasis , 2018, Respiration.

[21]  A. Chang,et al.  ‘Good enough’ is ‘not enough’ when managing indigenous adults with bronchiectasis in Australia and New Zealand , 2018, Respirology.

[22]  I. Masters,et al.  Pediatric bronchiectasis: No longer an orphan disease , 2016, Pediatric pulmonology.

[23]  M. Mantero,et al.  Quality standards for the management of bronchiectasis in Italy: a national audit , 2016, European Respiratory Journal.

[24]  M. Chatfield,et al.  Nasopharyngeal carriage and macrolide resistance in Indigenous children with bronchiectasis randomized to long-term azithromycin or placebo , 2015, European Journal of Clinical Microbiology & Infectious Diseases.

[25]  L. Hoffman,et al.  Three clinically distinct chronic pediatric airway infections share a common core microbiota. , 2014, Annals of the American Thoracic Society.

[26]  A. Chang,et al.  Children with Chronic Suppurative Lung Disease Have a Reduced Capacity to Synthesize Interferon-Gamma In Vitro in Response to Non-Typeable Haemophilus influenzae , 2014, PloS one.

[27]  R. Ware,et al.  Long-term azithromycin for Indigenous children with non-cystic-fibrosis bronchiectasis or chronic suppurative lung disease (Bronchiectasis Intervention Study): a multicentre, double-blind, randomised controlled trial. , 2013, The Lancet. Respiratory medicine.

[28]  S. Welham,et al.  National BTS bronchiectasis audit 2012: is the quality standard being adhered to in adult secondary care? , 2013, Thorax.

[29]  J. Mills,et al.  Terminology used to describe health care teams: an integrative review of the literature , 2013, Journal of multidisciplinary healthcare.

[30]  A. O'donnell,et al.  Global burden of non-cystic fibrosis bronchiectasis: A simple epidemiological analysis , 2012 .

[31]  P. Morris,et al.  Lower airway microbiology and cellularity in children with newly diagnosed non‐CF bronchiectasis , 2012, Pediatric pulmonology.

[32]  S. Allen,et al.  From the Australian Commission on Safety and Quality in Health Care , 2011, The Medical journal of Australia.

[33]  C. Goss,et al.  A story of success: continuous quality improvement in cystic fibrosis care in the USA , 2011, Thorax.

[34]  I. Masters,et al.  Longitudinal growth and lung function in pediatric non-cystic fibrosis bronchiectasis: what influences lung function stability? , 2010, Chest.

[35]  I. Masters,et al.  Longitudinal growth and lung function in pediatric non-CF bronchiectasis - what influences lung function stability? , 2010, ATS 2010.

[36]  B. Middel,et al.  Effects of Case Management for Frail Older People or Those With Chronic Illness: A Systematic Review , 2009, Nursing research.